Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why These 5 Stocks Are Making Headlines Today

It’s been a rather quiet morning on Wall Street, at least in terms of the performance of the overall market. In contrast to previous sessions, the S&P 500 is flat and the NASDAQ is off by only a few tenths of a point. Although the broader market may be inactive, five stocks in particular are making headlines, some with potentially far reaching ramifications. In this article we’ll examine the latest news on Allergan plc Ordinary Shares (NYSE:AGN), Pfizer Inc. (NYSE:PFE), Wynn Resorts, Limited (NASDAQ:WYNN), Constellation Brands, Inc. (NYSE:STZ), and Cree, Inc. (NASDAQ:CREE), and analyze what the smart money thinks of these companies.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

The big merger between Allergan plc Ordinary Shares (NYSE:AGN) and Pfizer Inc. (NYSE:PFE) is officially dead. Pfizer and Allergan originally planned to merge in what would have been a record-setting $160 inversion billion deal, one that would have saved Pfizer a substantial amount in taxes. The Treasury Department put an end to those benefits on Monday however, issuing new rules to curb the advantages of tax inversions, and in particular as they related to this particular merger. Pfizer will pay Allergan a $150 million breakup fee for its troubles. The latter company’s CEO Brent Saunders said the following in regards to the quashed deal:

“While we are disappointed that the Pfizer transaction will no longer move forward, Allergan is poised to deliver strong, sustainable growth built of a set of powerful attributes. Our pipeline is one of the strongest in the industry, loaded with 70 mid-to-late-stage programs including 14 expected approvals and 16 regulatory submissions in 2016 alone.”

Follow Allergan Inc (NYSE:AGN)
Trade (NYSE:AGN) Now!

Allergan plc Ordinary Shares (NYSE:AGN) is the most widely held stock among the funds in our database, with 159 elite firms holding Allergan shares as of the end of the fourth quarter. Meanwhile, 109 funds held Pfizer Inc. (NYSE:PFE) at the end of December, up from 97 funds at the end of September. Ken Fisher‘s Fisher Asset Management was among the funds that held shares in both stocks, including a holding of 32.3 million shares of Pfizer. Both stocks are up by around 3% this morning as investors begin to reassess and value the two companies on their stand-alone merits.

Follow Pfizer Inc (NYSE:PFE)
Trade (NYSE:PFE) Now!

On the next page, we examine the latest developments surrounding Wynn Resorts Limited, Constellation Brands Inc, and Cree Inc.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...